Facing hundreds of lawsuits over its role in fueling the US opioid epidemic, Purdue Pharma is in the midst of full-scale teardown — but that doesn’t mean its former leaders aren’t making off well. Coming off a stint driving RNAi therapy inclisiran to a buyout, former Purdue CEO Mark Timney has found a new home at the helm of a small biotech.
Trending:
Ex-Purdue Pharma chief Mark Timney, named in dozens of opioid lawsuits, nabs another biotech CEO gig